Article Text
PDF
Abstract
The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this paper I examine ethical issues relating to the efficacy and safety of these drugs. Pharmaceutical companies have a moral obligation to disclose all information in their possession bearing on the true risks and benefits of their drugs. Only then can patients make fully informed decisions about their treatment.
- FDA, Food and Drug Administration
- SSRI, selective serotonin reuptake inhibitors
- SSRIS
- antidepressants
- ethics
- psychiatry
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Recording and treatment of premenstrual syndrome in UK general practice: a retrospective cohort study
- Suicide - related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis
- Bayer to spend $ 20 m to correct misleading advertising for oral contraceptive Yaz
- The duty to be Well - informed: The case of depression
- Publication trends in newspapers and scientific journals for SSRIs and suicidality: a systematic longitudinal study
- SSRI use and risk of fractures among perimenopausal women without mental disorders
- FDA drug summaries: a simplification too far?
- Depression, depressive symptoms and treatments in women who have recently given birth: UK cohort study
- Direct to consumer advertising
- Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review